42 42C.SI iX Biopharma Ltd. Loading... : Investor Sentiment and Bull/Bear Views

The author argues IX Biopharma could benefit significantly from a US$41m sole-source US government development contract through the Defense Health Agency, which funds Phase 3 and regulatory work for an Emergency Use Authorization for Department of Defense use. A Section 564 declaration under the FD&C Act in September 2026 is cited as the statutory precondition for the FDA to consider an EUA, with the company expecting to complete its EUA submission in Q4 2026. The author views the EUA and US government contract as a massive driver to move the company to the next stage. Main risk is that the thesis depends on regulatory and contract execution, though the author does not explicitly state a risk.

IX Biopharma has secured a $41 million sole-source contract from the US Defense Health Agency to fund Phase 3 trials and regulatory work. The company is currently pursuing an Emergency Use Authorization for its product, with a submission expected in Q4 2026. The primary risk is the execution of the regulatory process and the dependency on US government procurement.